Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04024956
Other study ID # CIP-3
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 25, 2020
Est. completion date May 26, 2023

Study information

Verified date June 2023
Source Polyganics BV
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Polyganics BV (Groningen, The Netherlands), in close collaboration with University Hospital-Eppendorf (UKE) Hamburg, has developed the Sealing Device for use in hepato-pancreato-bilary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site. The Sealing Device has been challenged in pre-clinical testing (laboratory and in-vivo work), but has not been evaluated for safety and performance in humans. This investigation will be conducted to clinically assess the safety and performance of Sealing Device as a means to reduce bile and pancreatic juice leakage in hepato-pancreato-bilary (HPB) surgery. Secondarily, the control of minimal to moderate bleeding will be assessed. To achieve adequate representation of the primary objective, the study will contain two separate surgical patient groups: Liver and Pancreas. The primary objective of the study is to demonstrate safety and performance in reducing intra- and post-operative leakage (bile and pancreatic juices) by using the Sealing Device in patients undergoing elective hepatic resection or distal pancreatectomy. The study will be conducted as an open-label, single-arm, multicenter study with a 16 months follow up. Up to 80 patients (40 liver and 40 pancreas patients) will be enrolled at up to 7 sites in Europe.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date May 26, 2023
Est. primary completion date November 19, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Preoperative inclusion criteria: Subjects will be eligible according the following criteria: 1. Subjects who are able to provide a written informed consent prior to participating in the clinical investigation. 2. Subjects who are = 18 years old. 3. Subjects who are able to comply with the follow-up or other requirements. 4. Subjects who are planned for an elective hepatic resection or distal pancreatectomy. During the surgery, the patients also need to comply with the intraoperative criteria. Intraoperative inclusion criteria: Subjects will be eligible according the following criteria: 1. Patch is applied manually (during open procedure, conversion procedure, or laparoscopic assisted procedure). Exclusion Criteria: Preoperative exclusion criteria Subjects who meet any of the following criteria will be excluded from participation: 1. Female subjects who are pregnant and/or breastfeeding. 2. Subjects with a known allergy to any of the components of the Sealing Device (Polyurethane (SDPU), 8-ArmPEG40k-SC (SDA), Disodium Hydrogen Phosphate (Na2HPO4) (BS) and DC-Green #6 (SDD)). 3. Subject with bleeding disorders requiring anti-coagulation medication (except acetylsalicylic acid). 4. Subjects who receive double-coagulation. 5. Subjects who receive peritoneal dialysis. 6. Subjects who previously required liver transplantation. 7. Subjects with a presence of systemic infection. 8. Subject who previously participated in this study, or in any investigational drug- or device study within 30 days of screening. 9. Subjects undergoing a procedure requiring an anastomosis (e.g. Klatskin tumours or Whipple). Intraoperative exclusion criteria: Subjects who meet any of the following criteria will be excluded from participation: 1. Subjects with multivisceral resections, except resection of spleen. 2. Not able to apply the patch(es) according to the Instructions For Use. 3. Total surgery requiring > 3 HPB Sealing Devices of 10 x 5 cm (which equals a resection surface of more than 88cm2). Additional for liver group: 4. Subjects with a Grade 3 or 4 of bleeding after primary closure after liver transection (Lewis 2016). 5. Subjects with liver cirrhosis Grade C on the Child-Turcotte-Pugh score. Additional for pancreas group: 6. Subjects with a margin of < 1 cm between the defect and the portal vein.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Sealing Device
The Sealing Device is indicated for use in hepato-pancreato-biliary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site.

Locations

Country Name City State
Germany Universitats Klinikum Hamburg-Eppendorf Hamburg
Germany University Hospital Oldenburg Oldenburg

Sponsors (2)

Lead Sponsor Collaborator
Polyganics BV Genae

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bile leakage Incidence of post-operative bile leakage (International Study Group of Liver Surgery Bile leakage Grading Scale); categories in order of ascending severity: biochemical leak, Grade B or Grade C 30 days
Primary Pancreatic leakage Incidence of post-operative pancreatic juice leakage (International Study Group of Pancreas Surgery Grading Scale); categories in order of ascending severity: biochemical leak, Grade B or Grade C 30 days
Secondary Bleeding Intra-operative control bleeding Day 1
Secondary Leak-associated comorbidities Incidence of leak-associated comorbidities 16 months
Secondary re-intervention Incidence of re-intervention 16 months
Secondary Ease of Use Ease of Use of the device as measured by questionnaire Day 1
Secondary Post-operative bile leakage Incidence of post-operative bile leakage (liver only) 90 and 180 days
Secondary Post-hepatectomy haemorrhage (PHH) Incidence of post-operative bleeding (liver only) 30 days
Secondary Post-operative pancreatic juice leakage Incidence of post-operative pancreatic juice leakage (pancreas only) 90 and 180 days
Secondary Post-pancreatectomy haemorrhage (PPH) Incidence of post-operative bleeding (pancreas only) 30 days
Secondary (Serious) Adverse Device Effects Incidence of (Serious) Adverse Device Effects 16 months
Secondary Incidence of transfusion Incidence of transfusion 16 months
Secondary Length of hospital stay Length of hospital stay 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT06208579 - Feasibility and Effectiveness of Augmented Reality Assistance System for Pancreatic Surgery
Completed NCT00414908 - A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy Phase 3
Completed NCT00559364 - Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea Phase 3
Active, not recruiting NCT04431076 - Patient Reported Outcomes Measures to Predict Pancreatic Surgery Outcomes
Recruiting NCT05297136 - Preoperative Endoscopic Pancreatic Stent for Distal Pancreatectomy N/A
Completed NCT03060408 - Comparison of Fluid Requirements in Pancreatectomy: Laparotomy vs. Laparoscopy N/A
Recruiting NCT02230436 - Early Versus Late Drain Removal After Pancreatectomy: A Randomized Prospective Trial N/A
Completed NCT02509910 - Implementation of a GDT Algorithm for Major Surgery Patients N/A
Completed NCT01929902 - Evaluation of Efficacy and Accuracy of Aquamantys Device in General Surgery
Terminated NCT02617979 - Improving Mental and Physical Health and Decreasing Hospital Readmission After Pancreatectomy Through Enhanced Patient and Caregiver Education and Engagement N/A
Recruiting NCT06126601 - Incidence and Clinical Impact of Serum Hyperamylasemia (POH) After Pancreatectomy on Postoperative Outcome and Patient Safety
Completed NCT02623803 - Perioperative Intravenous Lidocaine Infusion for Patients Undergoing Laparoscopic and Open Pancreatectomies Phase 4
Terminated NCT02649023 - Deep Venous Thrombosis After Hepatobiliopancreatic Surgery
Completed NCT02814812 - Postoperative Comput Tomography as a Predictor of Postoperative Complications After Pancreatic Surgery N/A
Completed NCT06424431 - Methods of Pancreatic Stump Closure for Distal Pancreatectomy N/A
Active, not recruiting NCT04423731 - Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer
Recruiting NCT05856474 - Management of Traumatic Pancreas Transection
Not yet recruiting NCT05992857 - Pancreaticoduodenectomies With Complete Arterial Coverage by Retromesenteric Omentoplasty N/A
Completed NCT01950845 - Automated Versus Manual Fluid Management for High Risk Abdominal Surgical Patient. A Prospective, Randomized Trial N/A
Not yet recruiting NCT04850430 - Gastric Venous Reconstruction After Total Pancreatectomy N/A